22246-05-5

Basic information

• Product Name: 7-HYDROXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE
• Synonyms: 7-HYDROXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE;3,4-Dihydro-7-hydroxy-1(2H)-isoquinolinone;7-Hydroxy-3,4-dihyrdro-2-H-isoquinolin-1-one;3,4-dihydroisoquinoline-1,7-diol;1(2H)-Isoquinolinone, 3,4-dihydro-7-hydroxy-
• CAS NO: 22246-05-5
• Molecular Formula: C₉H₉NO₂
• Molecular Weight: 163.17
• Mol File: 22246-05-5.mol

Chemical Properties

• Appearance: /
• Density: 1.282
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 7-HYDROXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-HYDROXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(22246-05-5)
• EPA Substance Registry System: 7-HYDROXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE(22246-05-5)

Safety Data

• Hazardous Substances Data: 22246-05-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-HYDROXY-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE is used as a key intermediate compound in the synthesis of various amine compounds. One of its primary applications is in the preparation of amine compounds that act as SSAO/VAP-1 inhibitors. These inhibitors have potential therapeutic applications in treating various diseases, including cancer, by targeting specific enzymes involved in the progression of the disease.

InChI:InChI=1/C9H9NO2/c11-7-2-1-6-3-4-10-9(12)8(6)5-7/h1-2,5,11H,3-4H2,(H,10,12)

Upstream product

• 22246-04-4 7-methoxy-3,4-dihydro-2H-isoquinolin-1-one 
• 91247-71-1 2-4-methoxyphenylethylcarbamic acid methyl ester 
• 62372-08-1 4-hydroxyphenyl-2-ethylcarbamic acid methyl ester 
• 55-81-2 4-Methoxyphenethylamine 
• 38480-95-4 6-methoxy-1H-inden-1-one 
• 66491-03-0 7-amino-3,4-dihydroisoquinoline-1(2H)-one 
• 22245-96-1 7-nitro-3,4-dihydro-2H-isoquinolin-1-one 
• 1196-38-9 3,4-dihydroisoquinolin-1(2H)-one 
• 83-33-0 inden-1-one 
• 13623-25-1 6-methoxy-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 190604-11-6 7-(benzyloxy)-3,4-dihydroisoquinolin-1(2H)-one 
• 190604-12-7 (7-Benzyloxy-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid tert-butyl ester 
• 190604-14-9 [7-(4-Cyano-benzyloxy)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 1027994-02-0 {6-[2-(4-Carbamimidoyl-phenyl)-ethoxy]-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 
• 1026177-04-7 [1-Oxo-7-(4-thiocarbamoyl-benzyloxy)-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 1027514-28-8 [7-(4-Carbamimidoyl-benzyloxy)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 1026846-42-3 [7-(4-Methylsulfanylcarbonimidoyl-benzyloxy)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 190604-15-0 {7-[4-(tert-Butoxycarbonylamino-imino-methyl)-benzyloxy]-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 
• 1354030-55-9 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroisoquinolin-1(2H)-one 
• 1354030-67-3 7-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)-3,4-dihydroisoquinolin-1(2H)-one 
• 1354030-69-5 7-(4-(4-(2,3-dichlorophenyl)piperidin-1-yl)butoxy)-3,4-dihydroisoquinolin-1(2H)-one 
• 1354030-23-1 7-(3-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)propoxy)-3,4-dihydroisoquinolin-1(2H)-one 
• 1354030-25-3 UNC₉₉₇₅ 
• 1231892-74-2 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-1(2H)-one 

Relevant articles and documents

1,2,4-Triazole-3-Thione Analogues with a 2-Ethylbenzoic Acid at Position 4 as VIM-type Metallo-β-Lactamase Inhibitors

Metallo-β-lactamases (MBLs) are increasingly involved as a major mechanism of resistance to carbapenems in relevant opportunistic Gram-negative pathogens. Unfortunately, clinically efficient MBL inhibitors still represent an unmet medical need. We previou

Propionamide derivative and application for schizophrenia

The invention belongs to the field of medicines, and particularly relates to a propionamide derivative and application thereof in schizophrenia. The propionamide derivative is CY150112-9, and tests show that the in-vitro affinity of the propionamide derivative is similar to that of CY150112. The CY150112-9 has high affinity with 5-HT2A and D2 receptors, the affinity with 5-HT2A is higher than thatof D2 receptors, it is speculated that the CY150112-9 has a certain effect on negative symptoms while positive symptoms are improved, and the CY150112-9 has a low extrapyramidal side reaction. CY150112-9 also has certain affinity to D3 and 5-HT7, and it is speculated that CY150112-9 may have the effect of improving cognition clinically. And the maximum tolerance of CY150112-9 is higher than 112.

AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF

An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.

FLUOROALLYLAMINE DERIVATIVE AND USE THEREOF

The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

Synthesis and pharmacological evaluation of new 3,4-dihydroisoquinolin derivatives containing heterocycle as potential anticonvulsant agents

Two novel series of 3,4-dihydroisoquinolin with heterocycle derivatives (4a-t and 9a-e) were synthesized and evaluated for their anticonvulsant activity using maximal electroshock (MES) test and pentylenetetrazole (PTZ)-induced seizure test. All compounds were characterized by IR, 1H-NMR, 13C-NMR, and mass spectral data. Among them, 9-(exyloxy)-5,6-dihydro-[1,2,4]triazolo[3,4-a] isoquinolin-3(2H)-one (9a) showed significant anticonvulsant activity in MES tests with an ED50 value of 63.31 mg/kg and it showed wide margins of safety with protective index (PI > 7.9). It showed much higher anticonvulsant activity than that of valproate. It also demonstrated potent activity against PTZ-induced seizures. A docking study of compound 9a in the benzodiazepine (BZD)-binding site of γ-aminobutyric acidA (GABAA) receptor confirmed possible binding of compound 9a with the BZD receptors.

BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY

A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune

Facile synthesis of 5-To 7-membered benzolactam compounds via strongly facilitated electrophilic aromtic substitution reaction

We employed our system to activate aromatic ring-Tethered carbamate compounds with trifluoromethanesulfonic acid to obtain benzolactams with 5-To 7-membered rings, and examined the substrate scope and limitations of this activation method. In 5-membered ring formation, a halogen group on the aromatic ring did not greatly affect the reaction yield, but other electron-donating groups inhibited the cyclization reaction, and various side-reactions occurred. In 7-membered ring formation, eletron-donating groups on aromatic ring promoted the cyclization reaction, but cyclization of electron-deficient aromatic rings did not proceed well. The 6-membered ring formation reaction showed the greatest substrate generality.

FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS

The present invention relates to novel functionally selective ligands of dopamine D2 receptors, including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

Activation of electrophilicity of stable Y-delocalized carbamate cations in intramolecular aromatic substitution reaction: Evidence for formation of diprotonated carbamates leading to generation of isocyanates

Although cations with three heteroatoms, such as monoprotonated guanidine and urea, are stabilized by Y-shaped conjugation and such Y-conjugated cations are sufficiently basic to be further protonated (or protosolvated) to dications in strongly acid media, only O-monoprotonated species have been detected in the case of carbamates even in magic acid. We found that the trifluoromethanesulfonic acid-catalyzed cyclization of arylethylcarbamates proceeds to afford dihydroisoquinolones in high yield. In strong acids, methyl carbamates are fully O-monoprotonated, and these monocations do not undergo cyclization even under heating. But, as the acidity of the reaction medium is further increased, the cyclization reaction of methyl phenethylcarbamates starts to proceed as a first-order reaction, with a linear relationship between rate and acidity. The sign and magnitude of the entropy of activation ΔS ? were found to be similar to those of other AAc1 reactions. These results strongly support the idea that further protonation of the O-protonated carbamates is involved in the cyclization, but the concentration of the dications is very low and suggests that the rate-determining step is dissociation of methanol from the diprotonated carbamate to generate protonated isocyanate, which reacts with the aromatic ring. Therefore, O-protonated carbamates are weak bases in sharp contrast to other Y-shaped monocations.

Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT1A receptor and the serotonin transporter

The structure-activity relationship (SAR) for three series of lactam-fused chroman derivatives possessing 3-amino substituents was evaluated. Many compounds exhibited affinities for both the 5-HT1A receptor and the 5-HT transporter. Compounds 45 and 53 demonstrated 5-HT1A antagonist activities in the in vitro cAMP turnover model.